Geneticists from Guangzhou, China recently shocked the scientific community by publishing what appears to be the first attempt at using CRISPR--Cas9 genomic-editing technology to modify disease-associated DNAs from human embryos. The article appeared in the May 2015 issue of *Protein & Cell*.

The experiments did not go well. Although endogenous target genes were cleaved as expected---cleavage occurred in only about half of the embryos tested. Additionally, the researchers observed that the uptake of the "repair" sequence was inefficient, occurring in only a small fraction of the embryos. More seriously, a high degree of off-target mutations was observed. Given the dangers of heritable off-target mutations in the germline, as well as the polarizing ethical considerations that must be considered when modifying human genomes, this study solidifies concerns of many in the scientific community that we are a long way off from using the CRISPR--Cas9 system as a tool for human gene therapy. However, considering the potential specificity and inherent ease of the system, it seems unlikely that exploration and discussion of this tool as a means of treating human genetic disease will end any time soon.

The system holds much promise. First identified in bacteria as a defense mechanism against invading pathogens, CRISPR--Cas9 works by using a small guide RNA sequence that corresponds precisely to the DNA target of interest. When combined with the Cas9 nuclease, these highly-specific guide RNA--Cas9 complexes bind directly to the gene of interest and mediate the direct double-stranded cleavage of the target DNA. It is then possible to inactivate the gene, or to replace a defective gene with a healthy version. By modifying the enzymatic activity of Cas9, it is also possible to turn the gene on (instead of cleaving it), or to alter the gene\'s expression. One can envisage the limitless possibilities that such highly-specific, targeted genetic manipulation holds for biomedical research and medicine.

For example, scientists have employed CRISPR--Cas9 to effectively "cure" cells latently infected with HIV by excising the integrated proviral DNA from the host cell. Although these studies were performed ex vivo, given the difficulties researchers have faced in identifying and eliminating HIV reservoirs from infected patients, this approach would be a welcome addition to our arsenal of HIV therapeutics. There have also been proof-of-principle studies where other DNA viruses such as hepatitis B and papillomavirus have been successfully targeted---and one can imagine a future where clinicians may use CRISPR--Cas9 as an easy-to-generate, nimble antimicrobial option against not only well-known, but also against suddenly emerging, DNA-based viral and perhaps also bacterial pathogens.

Scientists have also used the system to treat genetically-based defects in animal disease models. One recent study employing a mouse model of hereditary tyrosinemia, for example, showed that injection of CRISPR--Cas9 complexes specifically targeting the defective disease-associated *Fah* gene resulted in successful expression of the wild-type gene in the livers of targeted mice, but only in a small fraction of the liver cells. However, the researchers were able to correct phenotypic weight loss if they first expanded these modified cells ex vivo before transplanting them back into the mice. Some amendments to disease-targeting approaches may therefore be necessary to see phenotypic effects at the whole animal level, depending on the mode of delivery, the gene being targeted, and the disease under consideration.

Although RNAi has revolutionized our ability to efficiently and cheaply "knock-down" a gene\'s function by targeting the cleavage of its messenger RNA, CRISPR--Cas9 has taken gene targeting to a new level by silencing the gene at the source. Hoping to overcome some of the off-targeting and sometimes incomplete suppression issues inherent with RNAi, researchers have turned to CRISPR--Cas9 not only for therapeutic applications, but also as a basic tool for screening gene function at both the individual gene as well as at the genome-wide level. Genome-wide screens have been performed using CRISPR to look for specific genes mediating resistance to cancer drugs and certain pathogens, for example, as well as toward understanding which genes may be involved in mediating specific disease outcomes such as lung metastasis. We are really only at the beginning of the era of using CRISPR as a genetic screening tool.

Despite the promise and utility of the CRISPR--Cas9 system, great challenges and worries remain regarding its application as a human therapeutic tool. Given the degree of unexpected off-target germline mutation rates observed in the Guangzhou human embryo study, safety and ethical concerns are naturally at the top of our list of concerns. When considering CRISPR--Cas9 as a therapeutic application, we must proceed with caution and due diligence, taking into consideration all ethical and scientific imperatives. In addition to improving specificity and eliminating off-target effects, technical challenges also remain regarding in vivo delivery, as well as the potential for immunogenicity of the complex.

"With great power, comes great responsibility." Although the origin of this quote is debatable, the message is not. We urge our readers to walk---and not run---toward embracing this next generation of gene therapy tools.
